Cargando…
Novel Nitrile Peptidomimetics for Treating COVID-19
COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Ni...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2022
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848505/ https://www.ncbi.nlm.nih.gov/pubmed/35291756 http://dx.doi.org/10.1021/acsmedchemlett.2c00030 |
| _version_ | 1784652265792995328 |
|---|---|
| author | Chia, C. S. Brian |
| author_facet | Chia, C. S. Brian |
| author_sort | Chia, C. S. Brian |
| collection | PubMed |
| description | COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure–activity relationship of key inhibitors described in the patent WO 2021/250648 A1. |
| format | Online Article Text |
| id | pubmed-8848505 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Chemical Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88485052022-02-16 Novel Nitrile Peptidomimetics for Treating COVID-19 Chia, C. S. Brian ACS Med Chem Lett COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure–activity relationship of key inhibitors described in the patent WO 2021/250648 A1. American Chemical Society 2022-02-03 /pmc/articles/PMC8848505/ /pubmed/35291756 http://dx.doi.org/10.1021/acsmedchemlett.2c00030 Text en Published 2022 by American Chemical Society https://pubs.acs.org/page/vi/chemistry_coronavirus_researchThis article is made available via the ACS COVID-19 subset (https://pubs.acs.org/page/vi/chemistry_coronavirus_research) for unrestricted RESEARCH re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Chia, C. S. Brian Novel Nitrile Peptidomimetics for Treating COVID-19 |
| title | Novel Nitrile Peptidomimetics for Treating COVID-19 |
| title_full | Novel Nitrile Peptidomimetics for Treating COVID-19 |
| title_fullStr | Novel Nitrile Peptidomimetics for Treating COVID-19 |
| title_full_unstemmed | Novel Nitrile Peptidomimetics for Treating COVID-19 |
| title_short | Novel Nitrile Peptidomimetics for Treating COVID-19 |
| title_sort | novel nitrile peptidomimetics for treating covid-19 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848505/ https://www.ncbi.nlm.nih.gov/pubmed/35291756 http://dx.doi.org/10.1021/acsmedchemlett.2c00030 |
| work_keys_str_mv | AT chiacsbrian novelnitrilepeptidomimeticsfortreatingcovid19 |